XML 47 R19.htm IDEA: XBRL DOCUMENT
v3.22.1

Other Financial Assets | 12 Months Ended
--- | ---
Dec. 31, 2021
Disclosure Of Other Financial Assets [Abstract] |
Other Financial Assets | OTHER FINANCIAL ASSETS Other financial assets consisted of the following:
| Financial assets - Total |  | As of
| (in € thousands) |  | 2019/12/31 |  | 2020/12/31 |  | 2021/12/31
| Equity investments |  | — |  |  | — |  |  | 3,133 |
| Loans |  | 307 |  |  | 352 |  |  | 388 |
| Deposits and guarantees |  | 396 |  |  | 418 |  |  | 397 |
| Liquidity contract |  | 1,023 |  |  | 688 |  |  | 513 |
| TOTAL |  | 1,727 |  |  | 1,458 |  |  | 4,431 |
| Financial assets - Current |  | As of
| (in € thousands) |  | 2019/12/31 |  | 2020/12/31 |  | 2021/12/31
| Loans |  | — |  |  | — |  |  | — |
| Deposits and guarantees |  | — |  |  | — |  |  | — |
| Liquidity contract |  | — |  |  | — |  |  | — |
| TOTAL |  | — |  |  | — |  |  | — |
| Financial assets - Non current |  | As of
| (in € thousands) |  | 2019/12/31 |  | 2020/12/31 |  | 2021/12/31
| Equity investments |  | — |  |  | — |  |  | 3,133 |
| Loans |  | 307 |  |  | 352 |  |  | 388 |
| Deposits and guarantees |  | 396 |  |  | 418 |  |  | 397 |
| Liquidity contract |  | 1,023 |  |  | 688 |  |  | 513 |
| TOTAL |  | 1,727 |  |  | 1,458 |  |  | 4,431 |
| Financial assets - Variations |  |  | As of |  | Increase |  | Decrease |  | As of |
| (in € thousands) |  |  | 31/12/2020 |  |  |  |  |  | 31/12/2021 |
| Equity investments |  |  | — |  |  | 3,133 |  |  | — |  |  | 3,133 |  |
| Loans |  |  | 352 |  |  | 36 |  |  | — |  |  | 388 |  |
| Deposits and guarantees |  |  | 418 |  |  | 107 |  |  | (128) |  |  | 397 |  |
| Liquidity contract |  |  | 688 |  | 0 |  | (175) |  | 513 |
| TOTAL |  |  | 1,458 |  |  | 3,276 |  |  | (303) |  |  | 4,431 |  |
The total amount of financial assets of the Company was €4,431 at December 31, 2021, up from €1,458 at December 31, 2020. This change is mainly due to the €3,000 investment representing a 10% equity stake taken by the Company in Genoscience Pharma in December 2021 through the subscription of new ordinary shares, plus directly related costs. The liquidity contract consists of a share buyback program contracted to an investment service provider in order to facilitate the listing of the Group's shares (the liquidity cash balance hereunder represents funds held by investment service provider, which are not available for general use to the Company): •As of December 31, 2021, the liquidity account had a cash balance of €513, and CMC-CIC Market Solutions holds on behalf of Genfit 137,012 shares, recorded as a deduction from equity. •As of December 31, 2020, the liquidity account had a cash balance of €688, and CMC-CIC Market Solutions holds on behalf of Genfit 88,929 shares, recorded as a deduction from equity. •As of December 31, 2019, the liquidity account had a cash balance of €1,023, and CMC-CIC Market Solutions holds on behalf of Genfit 18,132 shares, recorded as a deduction from equity. About the recognition of equity investment in Genoscience Pharma subscribed in December 2021: We have not completed the equity purchase in Genoscience Pharma for trading purposes. Therefore, pursuant to IFRS 9, we have elected to classify the equity in Genoscience Pharma we acquired in December 2021 as equity instruments recognized at fair value through other comprehensive income (OCI). Pursuant to IFRS 9.5.1.1, at the time of initial recognition in 2021, this investment in equity instruments has been measured at fair value, augmented of the transaction costs related to the purchase. The amount recognized in the balance sheet at December 31, 2021 corresponds to the subscription price agreed upon between the parties as representative of the value of Genoscience Pharma a few days before closing of the period. In accordance with IFRS 9.5.7.1b, for future closings, changes in fair value on these equity instruments will be recognized as OCI. This OCI may not be reused as profit or loss, including in the case of a sale. If applicable, only dividends related to the investment in equity instruments will be recognized as profit provided that all conditions are met (IFRS 9.5.7.6 and 5.7.1A). At this stage, and in accordance with the amendment to IFRS 13, as equity in Genoscience Pharma is not publicly traded on active markets, the fair value of this equity is measured on the basis of valuation methods relying entirely or in part on unobservable inputs such as quoted prices in inactive markets or the valuation based on multiples for non-listed securities.

X
- Definition Disclosure of other financial assets. + References No definition available. + Details
Name: | gnft_DisclosureOfOtherFinancialAssetsAbstract
Namespace Prefix: | gnft_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of other financial assets. + References No definition available. + Details
Name: | gnft_DisclosureOfOtherFinancialAssetsExplanatoryTextBlock
Namespace Prefix: | gnft_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration